News

Using AmerisourceBergen and Allscripts solutions, the alliance will focus on delivering healthcare providers with authorized electronic access to patient medication records and drug monitoring across the continuum of

Approximately one in four patients with poorly controlled idiopathic generalized epilepsy (IGE) having primary generalized tonic-clonic (PGTC) seizures became free from all types of seizures when Keppra (levetiracetam)

BioVeris entered into a license agreement with the University of Massachusetts Amherst (UMA) for rights to commercialize products for possible use in the prevention, diagnosis and treatment of

The companies will work together to discover, develop and commercialize novel therapies targeted against the liver X receptor (LXR), a nuclear hormone receptor thought to play a role

RapidFire lead discovery is a mass spectrometry-based technology that enables the high throughput screening of biochemical assays. The use of mass spectrometry allows for label-free screening of challenging

PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for cystic fibrosis (CF) and Duchenne muscular dystrophy, with

This license will expand Accentia’s pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market. Collegium plans to file a supplemental

Cephalon will acquire all of the outstanding share capital of Zeneus Holdings for approximately $360 million in cash. The transaction is expected to close no later than early

Under the agreement, Novartis has obtained worldwide licensing rights to investigational agent AT9311, an Astex cell cycle inhibitor that is currently completing preclinical studies. Novartis also has an